Priyanka Singh
Agilent Technologies, janssen pharmaceticals, Institut des Biomolécules Max Mousseron, Central Drug Research Institute
0000-0002-2941-8123
About
I am an experienced research and development scientist with multidisciplinary expertise in organic chemistry, oligonucleotide therapeutics, peptide chemistry, and small molecule drug discovery, with a strong focus on RNA therapeutics. I currently work as a Principal Scientist at Switch Therapeutics, where I contribute to the discovery and preclinical development of novel RNAi therapeutics.
I received my Ph.D. from CSIR-Central Drug Research Institute (CDRI), Lucknow, India, and completed my postdoctoral training at CNRS–Institute of Biomolecule Max Mousseron, Montpellier, France. My training in organic synthesis provided a strong foundation for solving complex chemical challenges related to nucleic acid therapeutics.
My career has focused on advancing RNA therapeutics from discovery through development. Previously, I contributed to oligonucleotide manufacturing and process development at Agilent Technologies and supported high-throughput oligonucleotide synthesis and purification efforts at Janssen Pharmaceuticals to accelerate RNA therapeutic discovery.
My expertise spans oligonucleotide synthesis, chemical modification, purification, analytical characterization, formulation development, manufacturing scale-up, and technology transfer. In addition to RNA therapeutics, I have experience in natural product synthesis, carbohydrate chemistry, heterocyclic chemistry, methodology development, peptide synthesis, and developing therapies targeting infectious diseases including tuberculosis, malaria, and leishmaniasis.
I have authored or co-authored sixteen international publications and am an inventor on one patent. My research interests focus on advancing innovative nucleic acid therapeutics through the integration of chemistry, biology, and translational drug development.
Employment
-
Agilent Technologies R&D Scientist2022 - 2023
-
janssen pharmaceticals Scientist2021 - 2022
Education
-
Institut des Biomolécules Max Mousseron Post-doctoral fellow2014 - 2016
-
Central Drug Research Institute PhD2008 - 2014
Projects & Funding
Projects & funding information is unavailable.
Publications (17)
- Bucky‐Bowl‐Derived Unnatural Amino Acids and Peptides: Synthesis and Substituent Effect on Bowl Inversion Dynamics and Electronic Structure Save
- Utilization of a novel siRNA platform technology to target APOE in the brain for the treatment of Alzheimer’s Disease Save
- The C-terminal segment of Leishmania major HslU: Toward potential inhibitors of LmHslVU activity Save
- The HslV Protease from Leishmania major and Its Activation by C-terminal HslU Peptides Save
- α-Amino acids with electrically charged and polar uncharged side chains as chiral synthon: Application to the synthesis of bioactive alkaloids (1996-Dec, 2013) Save
- Additional synthesis on thiophene-containing trisubstituted methanes (TRSMs) as inhibitors of M. tuberculosis and 3D-QSAR studies Save
- Additional synthesis on thiophene-containing trisubstituted methanes (TRSMs) as inhibitors of M. tuberculosis and 3D-QSAR studies Save
- THE MITOCHONDRIAL PROTEASOME- LIKE PEPTIDASE HSLVU, A NEW POTENTIAL TARGET FOR THE TREATMENT OF LEISHMANIASES AND TRYPANOSOMIASES Save
- Thiophene containing trisubstituted methanes [TRSMs] as identified lead against Mycobacterium tuberculosis Save
- Synthesis of polyhydroxylated indolizidines and piperidines from Garner's aldehyde: total synthesis of (−)-swainsonine, (+)-1,2-di-epi-swainsonine, (+)-8,8a-di-epi-castanospermine, pentahydroxy indolizidines, (−)-1-deoxynojirimycin, (−)-1-deoxy-altro-noj… Save